**Supplement table no. 4: Course of disease case no 4 (modified according to21)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Year** | **Date** | **Therapy** | **Staging** |
| **2010** | 09/2010 |  | initial diagnosis of a functional, gastric NET G2 and  liver, lymph node, bone metastases and peritoneal carcinomatosis  synaptophysin+, chromogranin A+, pan-cytokeratin +, CD 74+, VMAT2+, EP-CAM+, CDX2-, TTF1-, ISL1-, serotonin-  Ki-67 5%  PD-L1 5% |
|  | 09/2010 | atypical partial gastric resection, resection of multiple liver metastasis |  |
|  | 10/2010 | SSA (octreotide) |  |
| **2011** | 01-11/2011 | TACE (3 cycles) |  |
| **2011** | 03-09/2011 | PRRT |  |
|  | 09/2011 |  | mixed response: remission of osseus and hepatic metastasis |
| **2012** | 02-04/2012 | ipilimumab |  |
|  | 12/2012 | anterior rectum resection with appendectomy, splenectomy parietal peritonectomy with omentectomy and HIPEC | NEC G3, Ki-67 50% |
| **2013** | 01/13-12/2016 | brachytherapy  in afterloading technique (5 cycles) |  |
|  | 04-07/2013 | peg-interferon alpha2b |  |
|  | 08/2013-12/2014 | immunotherapy including vaccination of transfected autologous tumor |  |
|  | 11/2013 | relaparotomy with ileal tumor |  |
| **2014** | 01/2014 |  | PD |
|  | 11/2014 | pembrolizumab |  |
|  | 11/2014-06/2016 | pembrolizumab/ipililumab |  |
|  | 05/2014 | resection of pancreatic lymph node |  |
|  | 09/2014 | resection of metastases to the skin |  |
| **2015** | 02/2015 |  | PR |
|  | 07/2015 |  | SD |
| **2016** | 03/2016 | resection of peritoneal metastases, HIPEC |  |
|  | 04/2016 | radiosurgical radiation of metastasis OS sacrum (20Gy) |  |
|  | 08/2016 | immunotherapy including vaccination of transfected autologous tumor |  |
|  | 08/2016 | atezolizumab |  |
| **2017** | 02/2017 | robot-assisted mediastinal lymphadenectomy | no mutation of HER2NEU, BRAF, K-RAS, NRAS  MUC1 10% |
|  | 03/2017 | sunitinib |  |
|  | 04-05/2017 |  | SD |
|  | 04/2017-10/2019 | pembrolizumab/ipililumab |  |
|  | 06/2017 | everolimus |  |
|  | 05/2018-10/2019 |  | SD |
|  | 10/2019 |  | initial diagnosis of AML |
|  | 01/2020 |  | SD |

neuroendocrine tumor (NET), neuroendocrine carcinoma (NEC), partial Remission (PR), progressive disease (PD), peptide receptor radionuclide therapy (PRRT), transarterial chemoembolization (TACE), hyperthermic intraperitoneal chemotherapy (HIPEC), capecitabine/temzolomide (CAP/TEM), somatostatin analogue (SSA), single nucleotide variant (SNV)